Spruce Biosciences 2025 net loss narrows, secures $50 mln funding

Spruce Biosciences

09/03/2026 11:14

Overview

Biopharmaceutical firm's net loss for 2025 decreased compared to 2024

Company secured up to $50 mln in growth capital from Avenue Capital

Company appointed Dale Hooks as Chief Commercial Officer

Outlook

Spruce Biosciences plans BLA submission for TA-ERT in Q4 2026

Company secured $50 mln growth capital for TA-ERT launch

Spruce Biosciences aims for accelerated approval of TA-ERT

Result Drivers

R&D EXPENSES - Decrease in R&D expenses was due to cessation of tildacerfont development, offset by TA-ERT activities

FDA MEETINGS - Positive FDA meetings strengthened confidence in TA-ERT development for MPS IIIB

LONG-TERM DATA - Long-term data presented for TA-ERT showed potential as a disease-modifying treatment for MPS IIIB

Company press release: ID:nBwc197VXa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Net Income
-$38.97 mln
FY Income From Operations
-$36.51 mln
FY Operating Expenses
$36.51 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

Wall Street's median 12-month price target for Spruce Biosciences Inc is $190.00, about 240.1% above its March 6 closing price of $55.87

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)